Recent Updates
Recently added Catalysts
AHCO Positive Sentiment

AdaptHealth Corp. Announces Second Quarter 2026 Results

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AdaptHealth Corp. has reported its financial results for the second quarter of 2026, marking a successful period for the company. This quarter is notable as it is the first full quarter under a new exclusive capitated agreement with a major national integrated delivery network. The company remains a leader in providing home healthcare solutions.
Price reaction · baseline $10.83 (2026-08-03 close) · hit pre-market · clean, no other AHCO news in the window
day 0 close
-38%
day 1
-40%
day 3 · peak
-47.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Achieved financial results for Q2 2026.
  • Completed first full quarter under a new agreement.
  • Continues to lead in patient-centered healthcare solutions.

Full Press Release Details

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2026. Second Quarter Business Highlights Completed its first full quarter under the Company's exclusive capitated agreement with a large national integrated delivery networ

Frequently Asked Questions

What are the highlights of AdaptHealth's Q2 2026 results?

AdaptHealth reported its financial results for Q2 2026, completing its first full quarter under a new agreement.

What type of agreement did AdaptHealth complete in Q2 2026?

The company completed its first full quarter under an exclusive capitated agreement.

What services does AdaptHealth provide?

AdaptHealth provides patient-centered healthcare-at-home solutions, including medical equipment and supplies.

ShareAdd on Google
Tags: AHCO AdaptHealth financial results healthcare solutions capitated agreement
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$43M liquidity · $0M/mo burn
Low dilution risk